Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430533 · ClinicalTrials.gov registry record · Phase 1
Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
NCT01430533: Completed Phase 1 study, sponsored by LEO Pharma.
NCT01430533 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 240 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430533, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dermal sensitization potential of azelaic acid pre-foam formulation.
Primary Outcome
skin reactions will be assessed, using a standardized scoring scale
Interventions
- DRUG Water
- DRUG azelaic acid pre foam formulation
- DRUG Vehicle pre foam formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT01430533 record still lists
NCT01430533 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher).
The record links to 0 conditions, and to 3 interventions - of which Water is the first listed.
NCT01430533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01430533 about?
NCT01430533 is a clinical study titled "Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation". The purpose of this study is to determine the dermal sensitization potential of azelaic acid pre-foam formulation.
What is the current status of trial NCT01430533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2011-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01430533?
The interventions under investigation include: Water (DRUG), azelaic acid pre foam formulation (DRUG), Vehicle pre foam formulation (DRUG).
Who is sponsoring clinical trial NCT01430533?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01430533's enrollment target sits among peer trials
240 197th of 2000 higher than 1,789 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia